NeueHealth (NEUE) Q3 2024 earnings summary

Executive summary

• Achieved strongest financial performance to date in Q3 2024, with third consecutive quarter of positive Adjusted EBITDA, driven by both NeueCare and NeueSolutions segments.

• Served over 390,000 value-based consumers and 119,000 enablement services lives as of September 30, 2024, exceeding full-year guidance and representing significant year-over-year growth.

• Completed acquisition of full ownership of Centrum Health, streamlining operations and supporting value-driven care.

• Completed sale of California Medicare Advantage business for $500 million in January 2024, significantly reducing discontinued operations.

• Focused on diversifying consumer base across ACA Marketplace, Medicare, and Medicaid to mitigate market risks.

Financial highlights

• Q3 2024 consolidated revenue was $232.9 million, down from $269.4 million in Q3 2023; nine-month revenue was $704.0 million, down from $867.9 million year-over-year.

• Adjusted EBITDA for Q3 2024 was $9.4 million, up from $3.4 million in Q3 2023; year-to-date Adjusted EBITDA reached $17.0 million, up from $5.9 million in the prior year period.

• Net loss for Q3 2024 was $(40.4) million, a significant improvement from $(547.1) million in Q3 2023; net loss attributable to common shareholders was $(70.5) million.

• NeueCare segment Q3 2024 revenue was $83.9 million with operating income of $16.4 million; NeueSolutions segment revenue was $152.0 million with an operating loss of $5.8 million.

• Gross margin for Q3 2024 was $50.2 million, with improvement to 21.6% from 18.2% in Q3 2023.

Outlook and guidance

• 2024 guidance reaffirmed: consolidated revenue of approximately $950 million, Adjusted EBITDA between $15 million and $25 million, and 475,000–500,000 consumers served.

• NeueCare revenue guidance at $320 million; NeueSolutions at $640 million; expect to finish at or above the high end of consumer guidance.

• Adjusted operating cost ratio expected between 15%–16% (excluding corporate costs), 19%–20% including corporate costs, with expectations to finish at the low end.

• Management expects continued positive momentum and growth in 2025, focusing on expanding consumer base and deepening payor and provider relationships.

• Ongoing efforts to achieve positive operating cash flow and meet conditions for additional liquidity access.